By Stephen Nakrosis LumiraDx said Friday it will sell certain companies related to its point-of-care technology to Roche. Andrew Johnson, Lisa Rickelton and.
Shares of LumiraDx rose about 20%, to 76 cents in aftermarket trading. The transaction is expected to close by mid-2024, after which the acquired segment will become a part of Roche's diagnostics unit, the drugmaker said. Under the terms of the agreement, Roche will pay a purchase price of $295 million at the close of the transaction.
LumiraDx (NASDAQ:LMDX – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01), MarketWatch Earnings reports. LumiraDx had a negative net margin of 268.45% and a negative return on equity of 3,369.09%. The company had revenue […]
LumiraDx Limited (NASDAQ:LMDX – Free Report) shares dropped 7.8% during mid-day trading on Wednesday . The stock traded as low as $0.44 and last traded at $0.44. Approximately 248,248 shares traded hands during trading, a decline of 39% from the average daily volume of 404,353 shares. The stock had previously closed at $0.48. Wall Street […]
LumiraDx Limited (NASDAQ:LMDX – Free Report)’s stock price dropped 7.8% during trading on Wednesday . The stock traded as low as $0.44 and last traded at $0.44. Approximately 248,248 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 404,353 shares. The stock had previously closed at $0.48. Wall […]